Overview

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Midazolam